【中金：升翰森制药(03692.HK)目标价至23.3港元 维持“跑赢行业”评级】金十数据3月24日讯，中金发表报告指，翰森制药(03692.HK)去年收入122.61亿元人民币，按年增长21.3%；净利润43.72亿元人民币，按年增长33.4%，业绩略高于该行预期，主因产品对外授权的首付款记账以及阿美乐销售高速放量。报告指，由于阿美乐高增长，上调2025年盈利预测5.1%至44.05亿元人民币，并引入2026年盈利预测46.83亿元人民币。维持“跑赢行业”评级，根据SOTP法估值，考虑到上调盈利预测以及公司产品销售收入增速平稳，上调目标价10.3%至23.3港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.